Results 111 to 120 of about 13,011 (272)
Invasion inhibition in pancreatic cancer using the oral iron chelating agent deferasirox
BMC Cancer, 2020 Iron is required for cellular metabolism, and rapidly proliferating cancer cells require more of this essential nutrient. Therefore, iron regulation may well represent a new avenue for cancer therapy.
Shogo Amano +9 more
semanticscholar +1 more source
Pretransplant serum ferritin and C-reactive protein as predictive factors for early bacterial infection after allogeneic hematopoietic cell transplantation. [PDF]
, 2011 Although fluoroquinolones or other antibiotics are commonly used to prevent bacterial infections after hematopoietic cell transplantation (HCT), because of the growing presence of multidrug-resistant microorganisms, it is important to identify patients ...
Ichinohe, T +10 more
core +1 more source
Removal of Toxic Metabolites—Chelation: Manganese Disorders
Journal of Inherited Metabolic Disease, Volume 48, Issue 6, November 2025.ABSTRACT Manganese (Mn) overload is a characteristic of multiple disease entities, from acquired manganism upon environmental or occupational overexposure, to end‐stage liver disease and certain genetic disorders. The latter include hypermanganesaemia with dystonia 1 and 2 caused by pathogenic variants in the genes encoding the Mn transporters SLC30A10
Hendrik Vogt +4 more
wiley +1 more source
Deferasirox: appraisal of safety and efficacy in long-term therapy
Journal of Blood Medicine, 2013 Preeti Chaudhary, Vinod PullarkatJane Ann Nohl Division of Hematology, University of Southern California Keck School of Medicine, Los Angeles, CA, USAAbstract: Deferasirox is a once-daily, oral iron chelator that is widely used in the management of ...
Chaudhary P, Pullarkat V
doaj
Deferasirox desensitization [PDF]
The Journal of Allergy and Clinical Immunology: In Practice, 2016 Karen E, Bruner, Kevin M, White
openaire +2 more sources
Deferiprone versus Deferoxamine in Sickle Cell Disease: Results from a 5-year long-term Italian multi-center randomized clinical trial. [PDF]
, 2014 Blood transfusion and iron chelation currently represent a supportive therapy to manage anemia, vasculopathy and vaso-occlusion crises in Sickle-Cell-Disease.
Ballas, Samir K. +10 more
core +2 more sources
Delhi Journal of OphthalmologyWe report the case of a 15-year-old child with beta-thalassemia developing bilateral cataracts while receiving deferasirox, a newer iron chelator. She had been taking deferasirox for the past 10 years while receiving monthly blood transfusions.
Tushit Dhar +2 more
doaj +1 more source
Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine
Haematologica, 2013 Patients with β-thalassemia require iron chelation therapy to protect against progressive iron overload and non-transferrin-bound iron. Some patients fail to respond adequately to deferoxamine and deferasirox monotherapy while others have side effects ...
Robert W. Grady +5 more
doaj +1 more source
Optimising the diagnosis and the treatment of iron overload diseases [PDF]
, 2015 International audienceA number of human disorders are related to chronic iron overload, either of genetic or acquired origin. The multi-organ damage produced by iron excess leads, in adults and in children, to severe clinical consequences, affecting both
Brissot, Pierre
core +2 more sources